, one of the “must own” penny stocks for 2013 we covered at the end of 2012 has just come off 3 days of absolute explosiveness. Roth Capital Markets started coverage last week on RNN stock at a “Buy” rating, almost 1 year after we did when shares of the clinical stage biopharmaceutical company was trading at just 0.31. Having now gained as much as ...
14
JAN
JAN
0
Share
